1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Centus Gets European Bevacizumab Approval

Equidacent Rival To Avastin Gains Marketing Authorization

 
• By Dave Wallace

Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.

Thumbs_Up_EU
Centus has received formal European Commission approval for bevacizumab • Source: Shutterstock

Centus Biotherapeutics, the joint venture between Fujifilm Kyowa Kirin Biologics and AstraZeneca, has received formal European Commission approval for its Equidacent (bevacizumab) biosimilar version of Roche’s Avastin. The biosimilar received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in July. (Also see "EMA’s CHMP Is Set To Adopt Position On Another Avastin Biosimilar" - Generics Bulletin, 20 July, 2020.)

Commenting on the pan-European marketing authorization, Kyowa Kirin Biologics president and CEO Atsushi Matsumoto said the firm was “proud that Centus received the approval of Equidacent from the European Commission

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.